PD-1 inhibitors cause ILD in NSCLC patients with hypertension

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1925卷 / 1期
关键词：
D O I：
10.1007/s40278-022-23788-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11 / 11
相关论文
共 50 条
  • [41] The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis
    Yang, Y.
    Xie, Z.
    Pang, P.
    Wang, N.
    Liang, H.
    Zhao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1049
  • [42] PD-1 inhibitors in endometrial cancer
    Barroso-Sousa, Romualdo
    Ott, Patrick A.
    ONCOTARGET, 2017, 8 (63) : 106169 - 106170
  • [43] SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
    Chen, Yu
    Gao, Min
    Huang, Zhaoqin
    Yu, Jinming
    Meng, Xiangjiao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [44] Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost.
    Moskovitz, Mor Tal
    Matthews, Priscilla M.
    Pavel, Alexandra M.
    Xu, Wei
    Bradbury, Penelope Ann
    Liu, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [45] Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade
    Arbour, Kathryn C.
    Luu, Anh Tuan
    Luo, Jia
    Rizvi, Hira
    Plodkowski, Andrew J.
    Sakhi, Mustafa
    Huang, Kevin B.
    Digumarthy, Subba R.
    Ginsberg, Michelle S.
    Girshman, Jeffrey
    Kris, Mark G.
    Riely, Gregory J.
    Yala, Adam
    Gainor, Justin F.
    Barzilay, Regina
    Hellmann, Matthew D.
    CANCER DISCOVERY, 2021, 11 (01) : 59 - 67
  • [46] Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
    Wu, Yingcheng
    Lin, Lifeng
    Shen, Yanting
    Wu, Huiqun
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (11) : 3038 - 3040
  • [47] Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).
    Lau, Sally C. M.
    Le, Lisa W.
    Smith, Elliot Charles
    Chan, Sze Wah Samuel
    Ryan, Malcolm
    Brown, M. Catherine
    Hueniken, Katrina
    Eng, Lawson
    Patel, Devalben
    Chen, RuiQi
    Sung, Mike Ru
    Zer, Alona
    Bradbury, Penelope Ann
    Ohashi, Pamela S.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Liu, Geoffrey
    Leighl, Natasha B.
    Sacher, Adrian G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients
    He, Jiabei
    Pan, Yuanqing
    Guo, Yang
    Li, Baolan
    Tang, Yu
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (05) : 156 - 164
  • [49] Acquired resistance to PD-1 blockade in NSCLC.
    Schoenfeld, Adam Jacob
    Rizvi, Hira
    Memon, Danish
    Luo, Jia
    Preeshagul, Isabel Ruth
    Sauter, Jennifer L.
    Plodkowski, Andrew J.
    Vanderbilt, Chad
    Miller, Martin L.
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
    Peters, Solange
    Kerr, Keith M.
    Stahel, Rolf
    CANCER TREATMENT REVIEWS, 2018, 62 : 39 - 49
12345